1,604 results on '"Lim, Dawn"'
Search Results
2. Perspectives on Combination Medical Therapy in the Treatment of Acromegaly
3. Acromegaly: pathogenesis, diagnosis, and management
4. Three Year Outcomes of the Paul Glaucoma Implant for Treatment of Glaucoma
5. Management of corneal neovascularization: Current and emerging therapeutic approaches.
6. Re-evaluating absent clinical success after adrenalectomy in unilateral primary aldosteronism
7. Perspectives on Combination Medical Therapy in the Treatment of Acromegaly
8. Hypercoagulability in Cushing’s syndrome: From arterial to venous disease
9. Response to Letter to the Editor: One-Year Outcomes of Micropulse Cyclophototherapy for Primary Open-angle Glaucoma
10. Two-Year Outcomes of the Paul Glaucoma Implant for Treatment of Glaucoma
11. Cystic appearance on magnetic resonance imaging in bihormonal growth hormone and prolactin tumors in acromegaly
12. Treatment outcomes of micropulse cyclophototherapy in uveitic glaucoma
13. Retinal vein occlusion following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccination
14. Minimally symptomatic facial laser-induced retinal burn
15. Assessing utility, impact and adoption challenges of AI-enabled prescription advisory tool for type 2 diabetes management: perspectives from endocrinologists in a tertiary hospital (Preprint)
16. Novel therapeutics for dry eye disease
17. Anaphylactic reaction following administration of topical eyedrops
18. Aldosterone--potassium ratio predicts primary aldosteronism subtype
19. High prevalence of adrenal insufficiency at diagnosis and headache recovery in surgically resected Rathke’s cleft cysts—a large retrospective single center study
20. Uveitis and glaucoma: a look at present day surgical options
21. Expanding the use of salivary cortisol as a non-invasive outpatient test in the dynamic evaluation of suspected adrenal insufficiency
22. Impact of Microplastics on the Ocular Surface
23. SILENT EMERGENCY.
24. Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single center experience
25. Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review
26. The Management of Ocular Surface Squamous Neoplasia (OSSN)
27. Revenge of the Tick: Tick-Borne Diseases and the Eye in the Age of Climate Change and Globalisation
28. Dupilumab-associated ocular manifestations: A review of clinical presentations and management
29. Glaucoma drainage implant exposure: A review of aetiology, risks and repair considerations
30. The role of combination medical therapy in the treatment of acromegaly
31. Private Equity Opens the Door To Main Street.
32. Surgical Treatment of Angle-Closure Glaucoma
33. Beware what lurks on the surface – persistent contamination of high-touch surfaces on slit lamps despite regular cleaning
34. Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)
35. The Management of Ocular Surface Squamous Neoplasia (OSSN).
36. Distribution and abundance of sea urchins in Singapore reefs and their potential ecological impacts on macroalgae and coral communities
37. Tolerability and Efficacy of Long-Term Medical Therapy in Primary Aldosteronism
38. One-Year Outcomes of Micropulse Cyclophototherapy for Primary Open-angle Glaucoma
39. Corneal Cross-Linking: The Evolution of Treatment for Corneal Diseases
40. Efficacy and Safety of Repeated Micropulse Transscleral Diode Cyclophotocoagulation in Advanced Glaucoma
41. BOTH MEDICAL AND SURGICAL TREATMENT FOR UNILATERAL PRIMARY ALDOSTERONISM LEAD TO BLOOD PRESSURE IMPROVEMENTS
42. Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study
43. Use of anterior segment imaging and direct cyclopexy repair of cyclodialysis cleft.
44. Private Equity Gets Creative to Buy Time for More Gains. Clients Say Pay Me Now.
45. Blackstone's Gray Expects 'New Cycle' For Real Estate Market.
46. Blackstone Profit Misses Estimates as Real Estate Exits Slow.
47. Blackstone's Gray Hopes Biden Weighs 'Physical Toll' of New Term.
48. Blitzer Eyes Next Act After Building $35 Billion Blackstone Unit.
49. Biden's Biggest Donors Left Powerless to Sway Him to End Bid.
50. Biden's Biggest Donors Left Powerless to Sway Him to Quit Race.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.